Published in Nat Rev Cancer on December 01, 2004
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol (2005) 4.80
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov (2010) 3.84
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A (2007) 3.27
Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell (2007) 2.38
Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol (2007) 2.31
The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol (2006) 2.07
Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci U S A (2012) 1.66
Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol Cell Biol (2009) 1.51
Aurora-A kinase is essential for bipolar spindle formation and early development. Mol Cell Biol (2008) 1.44
Aurora B is required for mitotic chromatin-induced phosphorylation of Op18/Stathmin. Proc Natl Acad Sci U S A (2006) 1.43
Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta (2010) 1.33
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res (2008) 1.23
Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene (2013) 1.21
Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol (2009) 1.18
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood (2009) 1.16
Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. Br J Cancer (2012) 1.15
Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer (2010) 1.15
Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med (2008) 1.15
Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. Mol Biol Cell (2009) 1.15
Identification of small molecule inhibitors of the mitotic kinase haspin by high-throughput screening using a homogeneous time-resolved fluorescence resonance energy transfer assay. J Biomol Screen (2008) 1.13
Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer (2010) 1.13
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 1.12
SUMOylation modulates the function of Aurora-B kinase. J Cell Sci (2010) 1.10
Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors. J Med Chem (2012) 1.09
Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer (2005) 1.07
Proteome-scale Binary Interactomics in Human Cells. Mol Cell Proteomics (2016) 1.07
A single amino acid change converts Aurora-A into Aurora-B-like kinase in terms of partner specificity and cellular function. Proc Natl Acad Sci U S A (2009) 1.06
The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther (2011) 1.05
Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol (2007) 1.05
Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One (2009) 1.05
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res (2008) 1.04
Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer (2009) 1.04
Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. Mol Cell Biol (2010) 1.03
A current review of targeted therapeutics for ovarian cancer. J Oncol (2010) 1.02
Phosphatase inhibitor-2 balances protein phosphatase 1 and aurora B kinase for chromosome segregation and cytokinesis in human retinal epithelial cells. Mol Biol Cell (2008) 1.02
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res (2009) 1.01
Novel strategies for reversing platinum resistance. Drug Resist Updat (2009) 1.00
Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia (2012) 1.00
A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma. Clin Cancer Res (2012) 0.99
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2010) 0.98
Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res (2010) 0.98
A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A. ACS Chem Biol (2012) 0.98
FBXW7 is involved in Aurora B degradation. Cell Cycle (2012) 0.98
Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene (2011) 0.98
Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia (2009) 0.98
Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients. BMC Cancer (2012) 0.97
Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression. Neoplasia (2008) 0.95
Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors. ACS Chem Biol (2010) 0.94
Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer (2007) 0.93
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res (2011) 0.93
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 0.92
Aurora B prevents delayed DNA replication and premature mitotic exit by repressing p21(Cip1). Cell Cycle (2013) 0.91
Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J Gastroenterol (2011) 0.90
Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function. PLoS One (2012) 0.90
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs (2012) 0.90
Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer. PLoS One (2013) 0.90
Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation. Oncotarget (2014) 0.88
Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs (2012) 0.88
Targeting epigenetic regulations in cancer. Acta Biochim Biophys Sin (Shanghai) (2015) 0.88
Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochem Pharmacol (2011) 0.87
Crystal structure of human aurora B in complex with INCENP and VX-680. J Med Chem (2012) 0.87
Histone-modifying genes as biomarkers in hepatocellular carcinoma. Int J Clin Exp Pathol (2014) 0.86
Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe. Oncotarget (2015) 0.85
Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition. Mol Biol Cell (2015) 0.85
Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. Am J Pathol (2013) 0.85
A role for p38 in transcriptional elongation of p21 (CIP1) in response to Aurora B inhibition. Cell Cycle (2013) 0.85
The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations. J Comput Aided Mol Des (2011) 0.85
Benzo[e]pyridoindoles, novel inhibitors of the aurora kinases. Cell Cycle (2009) 0.85
MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas. Oncotarget (2016) 0.84
Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer Res (2012) 0.84
A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer. BMC Cancer (2013) 0.84
Differential expression of centrosomal proteins at different stages of human glioma. BMC Cancer (2010) 0.84
Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Drug Des Devel Ther (2015) 0.84
Molecular docking studies of benzimidazopyrimidine and coumarin substituted benzimidazopyrimidine derivatives: As potential human Aurora A kinase inhibitors. Bioinformation (2014) 0.84
CCAAT/enhancer-binding protein delta mediates tumor necrosis factor alpha-induced Aurora kinase C transcription and promotes genomic instability. J Biol Chem (2011) 0.84
Evolution of resistance to Aurora kinase B inhibitors in leukaemia cells. PLoS One (2012) 0.84
Overexpression of Aurora-A in primary cells interferes with S-phase entry by diminishing Cyclin D1 dependent activities. Mol Cancer (2011) 0.83
Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. Int J Clin Oncol (2010) 0.82
Loss-of-function genetic tools for animal models: cross-species and cross-platform differences. Nat Rev Genet (2016) 0.82
Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model. Carcinogenesis (2011) 0.81
MT7, a novel compound from a combinatorial library, arrests mitosis via inhibiting the polymerization of microtubules. Invest New Drugs (2009) 0.81
Induction of p21CIP1 protein and cell cycle arrest after inhibition of Aurora B kinase is attributed to aneuploidy and reactive oxygen species. J Biol Chem (2014) 0.81
EBNA3C regulates p53 through induction of Aurora kinase B. Oncotarget (2015) 0.80
3D-QSAR and molecular docking studies on derivatives of MK-0457, GSK1070916 and SNS-314 as inhibitors against Aurora B kinase. Int J Mol Sci (2010) 0.80
Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer. Int J Clin Exp Pathol (2015) 0.79
Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors. Oncotarget (2014) 0.79
Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther (2015) 0.78
P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. BMC Cancer (2011) 0.78
Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib). Mol Cancer (2012) 0.78
Inhibition of Aurora-B suppresses HepG2 cell invasion and migration via the PI3K/Akt/NF-κB signaling pathway in vitro. Exp Ther Med (2014) 0.78
A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Invest New Drugs (2014) 0.78
Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer. J Ovarian Res (2016) 0.78
A SILAC-based proteomics elicits the molecular interactome of alisertib (MLN8237) in human erythroleukemia K562 cells. Am J Transl Res (2015) 0.77
Multiplex imaging and cellular target identification of kinase inhibitors via an affinity-based proteome profiling approach. Sci Rep (2015) 0.77
Non-centrosomal TPX2-Dependent Regulation of the Aurora A Kinase: Functional Implications for Healthy and Pathological Cell Division. Front Oncol (2016) 0.77
Infrared ear thermometry compared with rectal thermometry in children: a systematic review. Lancet (2002) 5.18
ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. Cell (2010) 4.34
Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One (2009) 3.45
Intragenic enhancers act as alternative promoters. Mol Cell (2012) 2.85
RYBP-PRC1 complexes mediate H2A ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3. Cell (2012) 2.77
Genome-wide identification of TAL1's functional targets: insights into its mechanisms of action in primary erythroid cells. Genome Res (2010) 2.64
Molecular basis of drug resistance in aurora kinases. Chem Biol (2008) 2.03
MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood (2010) 1.88
Reduced dosage of ERF causes complex craniosynostosis in humans and mice and links ERK1/2 signaling to regulation of osteogenesis. Nat Genet (2013) 1.87
Mps1 kinase activity restrains anaphase during an unperturbed mitosis and targets Mad2 to kinetochores. J Cell Biol (2008) 1.82
Regulation of APC/C activity in oocytes by a Bub1-dependent spindle assembly checkpoint. Curr Biol (2009) 1.76
Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr (2004) 1.61
Global gene expression analysis of human erythroid progenitors. Blood (2011) 1.59
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Antivir Ther (2011) 1.53
The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS (2002) 1.50
Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med (2008) 1.42
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther (2011) 1.33
TNFα signals through specialized factories where responsive coding and miRNA genes are transcribed. EMBO J (2012) 1.21
Generation of bivalent chromatin domains during cell fate decisions. Epigenetics Chromatin (2011) 1.17
High frequency of HIV mutations associated with HLA-C suggests enhanced HLA-C-restricted CTL selective pressure associated with an AIDS-protective polymorphism. J Immunol (2012) 1.16
Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect Immun (2006) 1.15
Mitotic drivers--inhibitors of the Aurora B Kinase. Cancer Metastasis Rev (2009) 1.14
The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008. PLoS One (2011) 1.09
Nonspecific bridging-induced attraction drives clustering of DNA-binding proteins and genome organization. Proc Natl Acad Sci U S A (2013) 1.07
Differentially expressed, variant U1 snRNAs regulate gene expression in human cells. Genome Res (2012) 1.02
Cellular interference in craniofrontonasal syndrome: males mosaic for mutations in the X-linked EFNB1 gene are more severely affected than true hemizygotes. Hum Mol Genet (2013) 1.02
Ribosomal proteins Rps0 and Rps21 of Saccharomyces cerevisiae have overlapping functions in the maturation of the 3' end of 18S rRNA. Nucleic Acids Res (2003) 1.02
Dynamic analysis of gene expression and genome-wide transcription factor binding during lineage specification of multipotent progenitors. Cell Stem Cell (2013) 1.01
Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors. J Virol (2011) 1.00
IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol (2012) 0.97
Genome sequence of Rhodobacter sphaeroides Strain WS8N. J Bacteriol (2011) 0.96
Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Hum Vaccin (2007) 0.95
Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. J Antimicrob Chemother (2011) 0.94
Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin Vaccine Immunol (2009) 0.93
Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS (2002) 0.93
Outcomes of etomidate in severe sepsis and septic shock. Chest (2010) 0.92
Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization. J Mol Biol (2005) 0.91
Interferon-induced transmembrane protein-3 rs12252-C is associated with rapid progression of acute HIV-1 infection in Chinese MSM cohort. AIDS (2015) 0.91
Can a short period of micronutrient supplementation in older institutionalized people improve response to influenza vaccine? A randomized, controlled trial. J Am Geriatr Soc (2004) 0.90
A polar oxide with a large magnetization synthesized at ambient pressure. J Am Chem Soc (2005) 0.89
Efficacy of percutaneous electrical nerve stimulation for the treatment of chronic low back pain in older adults. J Am Geriatr Soc (2003) 0.88
The impact of HIV-1 infection and exposure on natural killer (NK) cell phenotype in Kenyan infants during the first year of life. Front Immunol (2012) 0.86
MIG: Multi-Image Genome viewer. Bioinformatics (2013) 0.85
Selfish spermatogonial selection: evidence from an immunohistochemical screen in testes of elderly men. PLoS One (2012) 0.85
Phenotypic characterization of HIV-specific CD8+ T cells during early and chronic infant HIV-1 infection. PLoS One (2011) 0.84
Solution, solid phase and computational structures of apicidin and its backbone-reduced analogs. J Pept Sci (2006) 0.83
Identification of new meningococcal serogroup B surface antigens through a systematic analysis of neisserial genomes. Vaccine (2009) 0.83
High-resolution analysis of cis-acting regulatory networks at the α-globin locus. Philos Trans R Soc Lond B Biol Sci (2013) 0.83
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother (2004) 0.83
Topical quinolone vs. antiseptic for treating chronic suppurative otitis media: a randomized controlled trial. Trop Med Int Health (2005) 0.83
Analysis of polycyclic aromatic hydrocarbons using desorption atmospheric pressure chemical ionization coupled to a portable mass spectrometer. J Am Soc Mass Spectrom (2014) 0.82
FITC-lectin avidity of Cryptococcus neoformans cell wall and capsular components. Mycologia (2010) 0.82
Mapping the stability diagram of a quadrupole mass spectrometer with a static transverse magnetic field applied. J Am Soc Mass Spectrom (2013) 0.82
Development of a large scale human complement source for use in bacterial immunoassays. J Immunol Methods (2013) 0.82
Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors. AIDS Rev (2005) 0.82
Membrane inlet mass spectrometry for homeland security and forensic applications. J Am Soc Mass Spectrom (2014) 0.81
2D wax-printed paper substrates with extended solvent supply capabilities allow enhanced ion signal in paper spray ionization. Analyst (2016) 0.80
Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy. PLoS Pathog (2010) 0.80
Saving Lives through visual health communication: a multidisciplinary team approach. J Vis Commun Med (2014) 0.79
Assessment of vaccine potential of the Neisseria-specific protein NMB0938. Vaccine (2009) 0.79
Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008. PLoS One (2012) 0.79
Human induced pluripotent stem cell-derived B lymphocytes express sIgM and can be generated via a hemogenic endothelium intermediate. Stem Cells Dev (2015) 0.78
Development of quadrupole mass spectrometers using rapid prototyping technology. J Am Soc Mass Spectrom (2009) 0.78
A Cross-Sectional Study on Attitudes to and Understanding of Risk of Acquisition of HIV: Design, Methods and Participant Characteristics. JMIR Res Protoc (2016) 0.78
Linking wheelchair kinetics to glenohumeral joint demand during everyday accessibility activities. Conf Proc IEEE Eng Med Biol Soc (2015) 0.78
Prioritizing genes of potential relevance to diseases affected by sex hormones: an example of myasthenia gravis. BMC Genomics (2008) 0.78
A multicentre cohort experience with double-boosted protease inhibitors. J Antimicrob Chemother (2009) 0.78
Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B. Vaccine (2007) 0.78
Monitoring of human chemical signatures using membrane inlet mass spectrometry. Anal Chem (2013) 0.78
Clinical predictors of a positive response to guided diagnostic block into the subacromial bursa. J Rehabil Med (2012) 0.77
Analysis of HIV-1 variation in blood and semen during treatment and treatment interruption. J Med Virol (2002) 0.77
Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma. J Antimicrob Chemother (2012) 0.77
Linear ion trap fabricated using rapid manufacturing technology. J Am Soc Mass Spectrom (2009) 0.76
Olanzapine and haloperidol: potential for neutropenia? Psychosomatics (2003) 0.76
Placental transfer of anti-group B Streptococcus immunoglobulin G antibody subclasses from HIV-infected and uninfected women to their uninfected infants. AIDS (2016) 0.76
A micropixelated ion-imaging detector for mass resolution enhancement of a QMS instrument. Anal Bioanal Chem (2014) 0.75
Asymmetrical features of mass spectral peaks produced by quadrupole mass filters. Rapid Commun Mass Spectrom (2003) 0.75
Photoinduced, family-specific, site-selective cleavage of TIM-barrel proteins. J Am Chem Soc (2009) 0.75
Olanzapine and quick-response hyperglycemia. Psychosomatics (2003) 0.75
Give leaders clear structures. Nurs Stand (2017) 0.75
Topical quinolone vs. antiseptic for treating chronic suppurative otitis media: a randomized controlled trial. Clin Otolaryngol (2005) 0.75
Factors influencing the QMF resolution for operation in stability zones 1 and 3. J Am Soc Mass Spectrom (2012) 0.75
Modelling real-time simultaneous saccharification and fermentation of lignocellulosic biomass and organic acid accumulation using dielectric spectroscopy. Bioresour Technol (2011) 0.75
Effect of an axial magnetic field on the performance of a quadrupole mass spectrometer. J Am Soc Mass Spectrom (2010) 0.75
Modelling mass analyzer performance with fields determined using the boundary element method. J Mass Spectrom (2010) 0.75
Oil-in-water monitoring using membrane inlet mass spectrometry. Anal Chem (2011) 0.75
M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. JCI Insight (2017) 0.75
From Facebook. Nurs Stand (2016) 0.75
Strain response of an instrumented intramedullary nail to three-point bending. J Med Eng Technol (2011) 0.75
By the way, doctor. I am starting to have trouble reading. But I have heard that wearing glasses to help me read will make my eyesight worse. Is that true? Harv Health Lett (2010) 0.75
A closed-loop inductive power control system for an instrumented strain sensing tibial implant. Conf Proc IEEE Eng Med Biol Soc (2014) 0.75
A quadrupole mass spectrometer for resolution of low mass isotopes. J Am Soc Mass Spectrom (2010) 0.75
The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. J Clin Invest (2017) 0.75
Uniforms a 'breeding ground'. Nurs Stand (2016) 0.75
Pay rise or better conditions? Nurs Stand (2017) 0.75
QMS in the third stability zone with a transverse magnetic field applied. J Am Soc Mass Spectrom (2011) 0.75
Monitoring real-time enzymatic hydrolysis of Distillers Dried Grains with Solubles (DDGS) by dielectric spectroscopy following hydrothermal pre-treatment by steam explosion. Bioresour Technol (2012) 0.75
Correction: Relationships between Mucosal Antibodies, Non-Typeable Haemophilus influenzae (NTHi) Infection and Airway Inflammation in COPD. PLoS One (2017) 0.75
Structural characterisation, stability and antibody recognition of chimeric NHBA-GNA1030: an investigational vaccine component against Neisseria meningitidis. Vaccine (2011) 0.75
A method of computing accurate 3D fields of a quadrupole mass filter and their use for prediction of filter behavior. J Am Soc Mass Spectrom (2012) 0.75